These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22499093)

  • 1. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.
    Song C; Xu Z; Miao J; Xu J; Wu X; Zhang F; Lin H; Li Z; Kaminski HJ
    Muscle Nerve; 2012 May; 45(5):668-675. PubMed ID: 22499093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting therapy to the neuromuscular junction: proof of concept.
    Kusner LL; Satija N; Cheng G; Kaminski HJ
    Muscle Nerve; 2014 May; 49(5):749-56. PubMed ID: 24037951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
    Zhang H; Lu S; Morrison SL; Tomlinson S
    J Biol Chem; 2001 Jul; 276(29):27290-5. PubMed ID: 11352906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.
    Wang Y; Li Y; Dalle Lucca SL; Simovic M; Tsokos GC; Dalle Lucca JJ
    J Neuroinflammation; 2010 Apr; 7():24. PubMed ID: 20380727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement.
    Spitzer D; Unsinger J; Bessler M; Atkinson JP
    Mol Immunol; 2004 Feb; 40(13):911-9. PubMed ID: 14725787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
    Soltys J; Halperin JA; Xuebin Q
    J Neuroimmunol; 2012 Mar; 244(1-2):63-9. PubMed ID: 22325826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).
    Stoiber H; Pintér C; Siccardi AG; Clivio A; Dierich MP
    J Exp Med; 1996 Jan; 183(1):307-10. PubMed ID: 8551237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.
    Heckmann JM; Uwimpuhwe H; Ballo R; Kaur M; Bajic VB; Prince S
    Genes Immun; 2010 Jan; 11(1):1-10. PubMed ID: 19675582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
    Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
    Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis.
    Auret J; Abrahams A; Prince S; Heckmann JM
    Neuromuscul Disord; 2014 Jun; 24(6):499-508. PubMed ID: 24703255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor.
    Zhong RK; Kozii R; Ball ED
    Br J Haematol; 1995 Oct; 91(2):269-74. PubMed ID: 8547061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury.
    van Denderen BJ; Salvaris E; Romanella M; Aminian A; Katerelos M; Tange MJ; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Sep; 64(6):882-8. PubMed ID: 9326415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells.
    Andoh A; Shimada M; Araki Y; Fujiyama Y; Bamba T
    Cancer Immunol Immunother; 2002 Feb; 50(12):663-72. PubMed ID: 11862418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decay-Accelerating Factor Creates an Organ-Protective Phenotype after Hemorrhage in Conscious Rats.
    Simovic MO; Falabella MJ; Le TD; DalleLucca JJ; Li Y
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade.
    Pérez-Alós L; Bayarri-Olmos R; Skjoedt MO; Garred P
    FASEB J; 2019 Nov; 33(11):12723-12734. PubMed ID: 31469600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.